These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 28264468)

  • 21. Top 100 bestselling drugs represent an arena struggling for new FDA approvals: drug age as an efficiency indicator.
    Polanski J; Bogocz J; Tkocz A
    Drug Discov Today; 2015 Nov; 20(11):1300-4. PubMed ID: 26160060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural products as leads to potential drugs: an old process or the new hope for drug discovery?
    Newman DJ
    J Med Chem; 2008 May; 51(9):2589-99. PubMed ID: 18393402
    [No Abstract]   [Full Text] [Related]  

  • 23. The mechanism of action and chemical synthesis of FDA newly approved drug molecules.
    Shen DD; Zhang YL; Li X; Bai YR; Xiong JF; Seng DJ; Zhang YD; Liu HM; Yuan S; Yang L
    Drug Dev Res; 2024 Sep; 85(6):e22260. PubMed ID: 39254376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects.
    Bai YR; Seng DJ; Xu Y; Zhang YD; Zhou WJ; Jia YY; Song J; He ZX; Liu HM; Yuan S
    Eur J Med Chem; 2024 Oct; 276():116706. PubMed ID: 39053188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceutical structure montages as catalysts for design and discovery.
    Njarðarson JT
    Future Med Chem; 2012 May; 4(8):951-4. PubMed ID: 22650237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A screening pattern recognition method finds new and divergent targets for drugs and natural products.
    Wassermann AM; Lounkine E; Urban L; Whitebread S; Chen S; Hughes K; Guo H; Kutlina E; Fekete A; Klumpp M; Glick M
    ACS Chem Biol; 2014 Jul; 9(7):1622-31. PubMed ID: 24802392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemoinformatic analysis of combinatorial libraries, drugs, natural products, and molecular libraries small molecule repository.
    Singh N; Guha R; Giulianotti MA; Pinilla C; Houghten RA; Medina-Franco JL
    J Chem Inf Model; 2009 Apr; 49(4):1010-24. PubMed ID: 19301827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2009 FDA drug approvals.
    Hughes B
    Nat Rev Drug Discov; 2010 Feb; 9(2):89-92. PubMed ID: 20118952
    [No Abstract]   [Full Text] [Related]  

  • 29. Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019.
    Yin Z; Hu W; Zhang W; Konno H; Moriwaki H; Izawa K; Han J; Soloshonok VA
    Amino Acids; 2020 Sep; 52(9):1227-1261. PubMed ID: 32880009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The year's new drugs & biologics 2015 - part II:Trends and highlights that marked a complicated year.
    Graul AI; Cruces E; Dulsat C; Tracy M
    Drugs Today (Barc); 2016 Feb; 52(2):131-63. PubMed ID: 27092342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural products to drugs: natural product derived compounds in clinical trials.
    Butler MS
    Nat Prod Rep; 2005 Apr; 22(2):162-95. PubMed ID: 15806196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of genotoxicity testing of FDA approved large molecule therapeutics.
    Sawant SG; Fielden MR; Black KA
    Regul Toxicol Pharmacol; 2014 Oct; 70(1):87-97. PubMed ID: 24932799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expanding the medicinally relevant chemical space with compound libraries.
    López-Vallejo F; Giulianotti MA; Houghten RA; Medina-Franco JL
    Drug Discov Today; 2012 Jul; 17(13-14):718-26. PubMed ID: 22515962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New drug and biological product approvals, 2012.
    Traynor K
    Am J Health Syst Pharm; 2013 Feb; 70(3):176, 178, 180. PubMed ID: 23327975
    [No Abstract]   [Full Text] [Related]  

  • 36. New drug and biological product approvals, 2013.
    Traynor K
    Am J Health Syst Pharm; 2014 Feb; 71(4):270. PubMed ID: 24481148
    [No Abstract]   [Full Text] [Related]  

  • 37. The impact of external innovation on new drug approvals: A retrospective analysis.
    Liu X; Thomas CE; Felder CC
    Int J Pharm; 2019 May; 563():273-281. PubMed ID: 30664998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2018 in review: FDA approvals of new molecular entities.
    Kinch MS; Griesenauer RH
    Drug Discov Today; 2019 Sep; 24(9):1710-1714. PubMed ID: 31158510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019.
    Dhodapkar MM; Ross JS; Ramachandran R
    JAMA Netw Open; 2023 Jun; 6(6):e2318889. PubMed ID: 37358857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New drug and biological product approvals, 2006.
    Traynor K
    Am J Health Syst Pharm; 2007 Feb; 64(4):342, 344. PubMed ID: 17299168
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.